Erlotinib
- PDF / 141,596 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 82 Downloads / 180 Views
1
Erlotinib Various toxicities: 7 case reports Seven patients with epidermal growth factor receptor mutant lung cancer developed various toxicities while receiving erlotinib for CNS metastases [see table].
Patient characteristics Patient/sex/ age (y)
Type of CNS metastases
Toxicity (grade)
1/F/44
brain
2/F/57 3/F/69 4/M/49 5/F/58 6/F/49
leptomeningeal leptomeningeal brain + leptomeningeal brain + leptomeningeal brain + leptomeningeal
7/M/60
brain + leptomeningeal
rash (2), CNS haemorrhage (1) diarrhoea (1) fatigue (1) CNS haemorrhage (1) rash (1) CNS haemorrhage (1), nausea (1), hair thinning (1) fatigue (1)
All patients began receiving monotherapy with pulsatile erlotinib 900-1500mg once per week for recurrent/ progressive CNS disease (5 patients) or newly diagnosed CNS metastases (2). Four patients had coexistent brain and leptomeningeal metastases, two patients had isolated brain metastases and one patient had isolated leptomeningeal metastases. They developed grade 1-2 toxicities during chemotherapy, including CNS haemorrhage (3 patients), rash (2), fatigue (2), diarrhoea (1), nausea (1) and hair thinning (1) [durations of treatment to reactions onset and outcomes not stated]. Grommes C, et al. Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-Oncology 13: 1364-1369, No. 12, Dec 2011. Available from: URL: http://dx.doi.org/1093/neuonc/nor121 803068504 USA
0114-9954/10/1394-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 24 Mar 2012 No. 1394
Data Loading...
